Result
Number: Indacaterol+tiotropium 570, Placebo+tiotropium 561

Differences between indacaterol+tio vs. tio+placebo

| Result Item                       | Value (mL) |
| :-------------------------------- | :--------- |
| FEV₁ AUC 5 min~8 h                | 120 (90~160) |
| COPD severity - moderate          | 130 (100~160) |
|             - severe              | 120 (90~150) |
| Smoking status - ex smoker        | 130 (100~170) |
|                 - current smoker  | 120 (90~160) |
| ICS use - non-users               | 120 (90~160) |
| Trough FEV₁ - users               | 130 (100~160) |
| COPD severity - moderate          | 90 (50~130) |
|                 - severe          | 70 (30~110) |
| Smoking status - ex smoker        | 70 (40~110) |
|                  - current smoker | 80 (40~130) |
| ICS use - non-users               | 70 (30~110) |
|           - users                 | 80 (50~120) |

### Patient reported symptoms and use of as-needed salbutamol
| Item                                          | Indacaterol+tiotropium | Placebo+tiotropium |
| :-------------------------------------------- | :--------------------- | :----------------- |
| Change from baseline symptom score (full 24 h)| -2.1 (0.20)            | -1.6 (0.21)        |
| Change from baseline symptom score (day-time) | -1.2 (0.10)            | -0.9 (0.10)        |
| Change from baseline symptom score (night-time)| -1.0 (0.10)            | -0.8 (0.10)        |
| Change from baseline salbutamol use (puff/day)| -2.5 (0.17)            | -1.3 (0.17)        |
| Days during treatment with no salbutamol use (%)| 43.2 (1.91)            | 34.2 (1.93)        |

### Adverse events (%)
| Item                             | Indacaterol+tiotropium | Placebo+tiotropium |
| :------------------------------- | :--------------------- | :----------------- |
| Cough                            | 10.4                   | 3.7                |
| Muscle spasm                     | 2.3                    | 0                  |
| Plasma potassium <3.5 mmol/L     | 2.3                    | 2.1                |
| Systolic BP-high                 | 2.3                    | 0.5                |
| QTc interval (absolute value)    | 3.2                    | 2.9                |

\*post-salbutamol for FEV₁ % and FEV₁/FVC and pre/post salbutamol for reversibility

## 근거표 5; LABA + LAMA vs LAMA

| Field                    | Indacaterol+tiotropium / Description                                                                                                                                                                                                                                                                                                                                                 | Placebo+tiotropium |
| :----------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | :----------------- |
| Author, year publication | Donald A Mahler et al., 2012                                                                                                                                                                                                                                                                                                                                                          |                    |
| Title                    | Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison                                                                                                                                                                                                            |                    |
| Country                  | Study 1: 186 centers in 14 countries                                                                                                                                                                                                                                                                                                                                                  |                    |
| Setting/Design           | Double-blind tiotropium 18 µg+Indacaterol 150 µg once daily vs. tiotropium 18 µg+placebo                                                                                                                                                                                                                                                                                             |                    |
| Time frame               | 12-week study                                                                                                                                                                                                                                                                                                                                                                         |                    |
| Randomization method     | An automated interactive voice response system and was stratified by COPD severity                                                                                                                                                                                                                                                                                                    |                    |
| Allocation concealment   | Yes (An automated interactive voice response system)                                                                                                                                                                                                                                                                                                                                  |                    |
| Blinding                 | The blinding of indacaterol and placebo continued until the study                                                                                                                                                                                                                                                                                                                     |                    |
| - Participants           | Yes                                                                                                                                                                                                                                                                                                                                                                                   |                    |
| - Investigators          | Yes                                                                                                                                                                                                                                                                                                                                                                                   |                    |
| - Outcome assessors      | Yes                                                                                                                                                                                                                                                                                                                                                                                   |                    |
| Intention-to-treat       | Yes                                                                                                                                                                                                                                                                                                                                                                                   |                    |
| Follow-up period         | 12-week                                                                                                                                                                                                                                                                                                                                                                               |                    |
| Loss to follow-up        | 29/572 for indacaterol+tiotropium                                                                                                                                                                                                                                                                                                                                                     | 37/570 for tiotropium+placebo group |
| ITT anlaysis             | Indacaterol+tiotropium                                                                                                                                                                                                                                                                                                                                                                | Placebo+tiotropium |
| Number                   | 572                                                                                                                                                                                                                                                                                                                                                                                   | 570                |
| Age                      | 63.1±8.83                                                                                                                                                                                                                                                                                                                                                                             | 62.84± 8.98        |
| Sex (M)                  | 63%                                                                                                                                                                                                                                                                                                                                                                                   | 68%                |
| Ethnicity (Caucasian)    | 77.8%                                                                                                                                                                                                                                                                                                                                                                                 | 79.3%              |
| FEV₁ %predicted (postBD\*) | 48.6 (9.74)                                                                                                                                                                                                                                                                                                                                                                             | 48.6 (9.76)        |
| FEV₁/FVC (postBD\*)      | 47.0 (10.21)                                                                                                                                                                                                                                                                                                                                                                          | 47.2 (9.53)        |
| FEV₁ reversibility (%)\* | 16.3 (15.85)                                                                                                                                                                                                                                                                                                                                                                          | 16.5 (16.27)       |
| Inclusion                | - Aged ≥40 years<br>- A smoking history of ≥10 pack yrs<br>- A diagnosis of moderate-to-severe COPD (postbronchodilator 30≤FEV₁<65, FEV₁/FVC<0.7)                                                                                                                                                                                                                                   |                    |
| Exclusion                | - A history of asthma<br>- History of exacerbation within the previous 6weeks                                                                                                                                                                                                                                                                                                         |                    |
| Intervention             | Indacaterol+tiotropium<br>Indacaterol 150 µg once daily<br>Tiotropium, 18 µg once daily                                                                                                                                                                                                                                                                                               | Placebo+tiotropium<br>tiotropium, 18 µg once daily |

<PAGE>109